Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells
Conclusions:
We suggest to evaluate ZAP-70 expression in routine settings using the T/B Ratio-method, given the operator and laboratory independent feature of this approach. We propose the 3.0 T/B Ratio value as optimal cut-off to discriminate ZAP-70+ (T/B Ratio less than 3.0) from ZAP-70- (T/B Ratio more/equal than 3.0) cases. (Source: Journal of Translational Medicine)...
POSTED 03/07/2010 at 06:00 PM --
|
Intracellular Succinylation of 8-Chloroadenosine and Its Effect on Fumarate Levels [Bioenergetics]
8-Chloroadenosine (8-Cl-Ado) is a ribosyl nucleoside analog currently in phase I testing for the treatment of chronic lymphocytic leukemia (CLL). 8-Cl-Ado activity is dependent on adenosine kinase and requires intracellular accumulation of 8-Cl-Ado as mono-, di-, and tri-phosphates. In the current study with four mantle cell lymphoma cell lines, we report a new major metabolic pathway for 8-Cl-Ado intracellular metabolism, the formation of succinyl-8-chloro-adenosine (S-8-Cl-Ado) and its monophosphate (S-8-Cl-AMP). 8-Cl-AMP levels were highly associated with S-8-Cl-AMP levels and reached a steady-state prior to the secondary metabolites, 8-Cl-ATP and S-8-Cl-Ado. Consistent with fumarate as a required substrate for formation of succinyl-8-Cl-adenylate metabolites, the S-8-Cl-adenylate conce......
POSTED 03/05/2010 at 08:37 AM --
|
NICE Set To Recommend Rituximab For Relapsed Or Refractory Chronic Lymphocytic Leukaemia
The National Institute for Health and Clinical Excellence (NICE) has today (4 March) issued final draft guidance recommending the drug rituximab(MabThera) as a treatment for certain patients with relapsed or refractory chronic lymphocytic leukaemia. This draft is now with consultees who have the opportunity to appeal against the proposed recommendations before final guidance is published later this year. Chronic lymphocytic leukaemia is a cancer of the white blood cells and is the most common form of leukaemia in the UK... (Source: Health News from Medical News Today)...
POSTED 03/04/2010 at 10:00 PM --
|
NICE Set To Recommend Rituximab For Relapsed Or Refractory Chronic Lymphocytic Leukaemia
The National Institute for Health and Clinical Excellence (NICE) has today (4 March) issued final draft guidance recommending the drug rituximab(MabThera) as a treatment for certain patients with relapsed or refractory chronic lymphocytic leukaemia... (Source: Cancer / Oncology News From Medical News Today)...
POSTED 03/04/2010 at 10:00 PM --
|
Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression
This study demonstrates the existence of separate MV phenotypes during leukemic disease progression and underscores the important role of MVs in activation of the tumor microenvironment. (Source: Blood)...
POSTED 03/04/2010 at 11:00 AM --
|
Pharmacological activation of the p53 pathway in haematological malignancies
p53 gene mutations are rarely detected at diagnosis in common haematological cancers such as multiple myeloma (MM), acute myeloid leukaemia (AML), chronic lymphocytic leukaemia (CLL) and Hodgkin's disease (HD), although their prevalence may increase with progression to more aggressive or advanced stages. Therapeutic induction of p53 might therefore be particularly suitable for the treatment of haematological malignancies. Some of the anti-tumour activity of current chemotherapeutics has been derived from activation of p53. However, until recently it was unknown whether p53 signalling is functional in certain haematological cancers including MM and if p53 activity is sufficient to trigger an apoptotic response. With the recent discovery of nutlins, which represent the first highly selective......
POSTED 03/04/2010 at 09:42 AM --
|
NICE issues Final Appraisal Determination on rituximab for relapsed chronic lymphocytic leukaemia
Source: NICE
Area: News
NICE has issued its Final Appraisal Determination on rituximab for relapsed chronic lymphocytic leukaemia, which contained the following preliminary recommendations:
. Rituximab in combination with fludarabine and cyclophosphamide is recommended as a treatment option for people with relapsed or refractory chronic lymphocytic leukaemia except when the condition is refractory to fludarabine (i.e. not responded to fludarabine or has relapsed within 6 months of treatment) or has previously been treated with rituximab.
. Rituximab in combination with fludarabine and cyclophosphamide is recommended only in the context of research for people with relapsed or refractory chronic lymphocytic leukaemia that has previously been treated with ritu......
POSTED 03/03/2010 at 06:00 PM --
|
Fludarabine and cyclophosphamide with rituximab prolongs progression-free survival in previously treated CLL
Source: JCO
Area: News
According to research published early online in the Journal of Clinical Oncology, rituximab in combination with fludarabine and cyclophosphamide (R-FC) significantly improved the outcome of patients with previously treated Chronic Lymphocytic Leukeamia (CLL).
Researchers compared six cycles of rituximab plus fludarabine and cyclophosphamide (R-FC; n=276) with six cycles of fludarabine and cyclophosphamide alone (FC; n=276) in patients with previously treated CLL. The trial involved a total of 552 patients with Binet stage A (10%), B (59%), or C (31%) disease.
The following results were reported: . After a median follow-up time of 25 months, rituximab significantly improved progression-free survival (hazard ratio = 0.65; P < 0.001; media......
POSTED 03/01/2010 at 06:00 PM --
|
The Lysosomotropic Agent, Hydroxychloroquine, Delivered in a Biodegradable Nanoparticle System, Overcomes Drug Resistance of B-Chronic Lymphocytic Leukemia Cells In Vitro
Cancer Biotherapy & Radiopharmaceuticals Feb 2010, Vol. 25, No. 1: 97-103. (Source: Cancer Biotherapy and Radiopharmaceuticals)...
POSTED 02/28/2010 at 10:56 PM --
|
Unexpected detection of monoclonal B-cell lymphocytosis in a HLA-matched sibling donor on the day of allogeneic stem cell transplantation for a patient with chronic lymphocytic leukaemia: clinical outcome
(Source: British Journal of Haematology)...
POSTED 02/28/2010 at 06:00 PM --
|
Urolithiasis in patients suffering from malignant hematologic diseases.
CONCLUSION: The incidence of urolithiasis for malignant hematologic patients was significantly higher than that for the control group.
PMID: 20191017 [PubMed - in process] (Source: Yonsei Medical Journal)...
POSTED 02/28/2010 at 06:00 PM --
|
A novel Rag2-/-{gamma}c-/--xenograft model of human CLL
Easily reproducible animal models that allow for study of the biology of chronic lymphocytic leukemia (CLL) and to test new therapeutic agents have been very difficult to establish. We have developed a novel transplantable xenograft murine model of CLL by engrafting the CLL cell line MEC1 into Rag2–/–c–/– mice. These mice lack B, T, and natural killer (NK) cells, and, in contrast to nude mice that retain NK cells, appear to be optimal recipient for MEC1 cells, which were successfully transplanted through either subcutaneous or intravenous routes. The result is a novel in vivo model that has systemic involvement, develops very rapidly, allows the measurement of tumor burden, and has 100% engraftment efficiency. This model closely resembles aggressive human CLL and co......
POSTED 02/25/2010 at 11:22 AM --
|
Merkel Cell Carcinoma in the Peripheral Blood of a Patient With Concomitant Chronic Lymphocytic Leukemia and Multiple Myeloma [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)...
POSTED 02/24/2010 at 05:01 PM --
|
Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia
The combination of pentostatin (P), cyclophosphamide (C), and rituximab (R) achieved an overall response (OR) rate >90%, with >40% complete responses (CRs) in patients with untreated chronic lymphocytic leukemia (CLL).To evaluate whether the tolerability of this regimen could be enhanced without sacrificing efficacy, a phase 2 trial was conducted of P and R without C, using a higher P dose (4 mg/m2). Among the 33 patients enrolled, 82% were male, the median age was 65 years (9 patients were aged [ge]70 years), and 64% were classified as having Rai stage III to IV disease.The OR rate was 76%, with 9 CRs (27%), 5 nodular partial responses, and 11 partial responses (PRs) reported. At the time of last follow-up, 29 of 33 patients were still alive at a median follow-up of 14 months (range, 1-34......
POSTED 02/23/2010 at 06:00 PM --
|
Chronic lymphocytic leukemia presenting with symptomatic peritoneal infiltration
We report the very rare case of CLL diagnosis in a patient suffering from epigastralgia due to peritoneal infiltration. (Source: Leukemia Research)...
POSTED 02/23/2010 at 08:33 AM --
|
US FDA approves Rituxan/MabThera for the most common type of adult leukemia
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) approved Rituxan/MabThera (rituximab) plus fludarabine and cyclophosphamide (FC) chemotherapy for people with either previously untreated (first-line) or previously treated (relapsed or refractory) CD20-positive chronic lymphocytic leukemia (CLL). (Source: World Pharma News)...
POSTED 02/22/2010 at 06:00 PM --
|
Rituxan Approved for Chronic Lymphocytic Leukemia
Title: Rituxan Approved for Chronic Lymphocytic LeukemiaCategory: Health NewsCreated: 2/19/2010 12:10:00 PMLast Editorial Review: 2/22/2010 (Source: MedicineNet Cancer General)...
POSTED 02/22/2010 at 01:00 AM --
|
Rituxan Approved for Chronic Lymphocytic Leukemia
Title: Rituxan Approved for Chronic Lymphocytic LeukemiaCategory: Health NewsCreated: 2/19/2010 12:10:00 PMLast Editorial Review: 2/22/2010 (Source: MedicineNet Skin General)...
POSTED 02/22/2010 at 01:00 AM --
|
Rituximab for the Treatment of Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukaemia
(Source: Drugs)...
POSTED 02/20/2010 at 08:12 AM --
|
US FDA Approves Rituxan/MabThera For The Most Common Type Of Adult Leukemia
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) approved Rituxan/MabThera (rituximab) plus fludarabine and cyclophosphamide (FC) chemotherapy for people with either previously untreated (first-line) or previously treated (relapsed or refractory) CD20-positive chronic lymphocytic leukemia (CLL). CLL is the most common type of leukemia in adults, accounting for approximately 30-40% of all forms of leukemia in Western countries. Overall incidence of CLL is around four per 100,000 and is 50% more common in men than in women1... (Source: Health News from Medical News Today)...
POSTED 02/20/2010 at 04:00 AM --
|
